These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 7351152)
21. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Cohn JN Eur Heart J; 1988 Jan; 9 Suppl A():171-3. PubMed ID: 3044793 [TBL] [Abstract][Full Text] [Related]
22. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Cohn JN; Archibald DG; Francis GS; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Flohr KH Circulation; 1987 May; 75(5 Pt 2):IV49-54. PubMed ID: 3552302 [TBL] [Abstract][Full Text] [Related]
23. Isosorbide dinitrate and hydralazine in blacks with heart failure. Eisenberger AB N Engl J Med; 2005 Mar; 352(10):1041-3; author reply 1041-3. PubMed ID: 15761995 [No Abstract] [Full Text] [Related]
24. Isosorbide dinitrate and hydralazine in blacks with heart failure. Bellin EY N Engl J Med; 2005 Mar; 352(10):1041-3; author reply 1041-3. PubMed ID: 15761996 [No Abstract] [Full Text] [Related]
25. [Vasodilator agents in the treatment of cardiac insufficiency]. Bertel O Ther Umsch; 1984 Feb; 41(2):117-24. PubMed ID: 6424258 [No Abstract] [Full Text] [Related]
26. Novel heart failure drug may offer options for you. Heart Advis; 2005 Sep; 8(9):2. PubMed ID: 16637097 [No Abstract] [Full Text] [Related]
27. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. Taylor AL; Ziesche S; Yancy C; Carson P; D'Agostino R; Ferdinand K; Taylor M; Adams K; Sabolinski M; Worcel M; Cohn JN; N Engl J Med; 2004 Nov; 351(20):2049-57. PubMed ID: 15533851 [TBL] [Abstract][Full Text] [Related]
29. BiDil for heart failure. Med Lett Drugs Ther; 2005 Sep; 47(1218):77-8. PubMed ID: 16186789 [TBL] [Abstract][Full Text] [Related]
30. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure. Cohn JN Herz; 1991 Sep; 16 Spec No 1():267-71. PubMed ID: 1820292 [TBL] [Abstract][Full Text] [Related]
31. [Treatment of heart failure with vasodilators]. Bolte HD Internist (Berl); 1980 Dec; 21(12):753-9. PubMed ID: 6451599 [No Abstract] [Full Text] [Related]
32. [Vasodilators in heart failure? Basic principles and its role in practice]. Fischer E; Siegenthaler W Dtsch Med Wochenschr; 1981 Sep; 106(39):1263-6. PubMed ID: 6123424 [No Abstract] [Full Text] [Related]
33. Introduction: Facts and fictions: BiDil and the resurgence of racial medicine. Dorr GM; Jones DS J Law Med Ethics; 2008; 36(3):443-8. PubMed ID: 18840234 [No Abstract] [Full Text] [Related]
34. Isosorbide dinitrate and hydralazine in blacks with heart failure. Moran AE; Cooper RS N Engl J Med; 2005 Mar; 352(10):1041-3; author reply 1041-3. PubMed ID: 15758018 [No Abstract] [Full Text] [Related]
35. Pharmacodynamic basis of the use of vasodilators in the treatment of heart failure. Taylor SH Med J Aust; 1980 Jul; 2(SP1):19-35. PubMed ID: 6775178 [No Abstract] [Full Text] [Related]
36. [Vasodilator therapy in cardiac failure]. Akatsuka N Nihon Rinsho; 1993 May; 51(5):1276-80. PubMed ID: 8101237 [TBL] [Abstract][Full Text] [Related]
37. Race and a heart drug. Peota C Minn Med; 2005 Mar; 88(3):11. PubMed ID: 15852585 [No Abstract] [Full Text] [Related]